Black Diamond Therapeutics (BDTX) Operating Income (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Operating Income came in at -$11.3 million in Q1 2026, down 120.65% YoY from $54.5 million in Q1 2025, and up 36.06% on a QoQ basis from -$17.6 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Operating Income (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Operating Income data on file, last reported at -$11.3 million in Q1 2026.
- Quarterly Operating Income fell 120.65% year-over-year to -$11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.3 million (down 1230.01% YoY) and the FY2025 annual result came in at $12.5 million, up 115.89% from the prior year.
- Operating Income grew to -$11.3 million in Q1 2026, from -$17.6 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $54.5 million in Q1 2025 to a low of -$25.7 million in Q1 2022.
- A 5-year average of -$15.1 million and a median of -$20.2 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2025 — Operating Income soared 369.34% — and 2026, when it slumped 120.65%.
- Tracing BDTX's Operating Income over 5 years: stood at -$21.9 million in 2022, then rose by 4.56% to -$20.9 million in 2023, then gained by 12.37% to -$18.3 million in 2024, then rose by 3.64% to -$17.6 million in 2025, then surged by 36.06% to -$11.3 million in 2026.
- The last three Operating Income figures came in at -$11.3 million (Q1 2026), -$17.6 million (Q4 2025), and -$11.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | -12.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.06 Mn |
| Mar 31, 2026 | -11.26 Mn |
| Dec 31, 2025 | -17.61 Mn |
| Sep 30, 2025 | -10.98 Mn |
| Jun 30, 2025 | -13.42 Mn |
| Mar 31, 2025 | 54.53 Mn |
| Dec 31, 2024 | -18.28 Mn |
| Sep 30, 2024 | -18.13 Mn |
| Jun 30, 2024 | -22.13 Mn |
| Mar 31, 2024 | -20.25 Mn |
| Dec 31, 2023 | -20.86 Mn |
| Sep 30, 2023 | -24.01 Mn |
| Jun 30, 2023 | -20.03 Mn |
| Mar 31, 2023 | -21.56 Mn |
| Dec 31, 2022 | -21.85 Mn |
| Sep 30, 2022 | -22.12 Mn |
| Jun 30, 2022 | -23.17 Mn |
| Mar 31, 2022 | -25.68 Mn |
| Dec 31, 2021 | -26.08 Mn |
| Sep 30, 2021 | -35.36 Mn |